Search

everythinglearnresearchcommunity

for

Search:↓

Topical Vitamin D3 may stimulate hair growth and has been used for Alopecia Areata. There is a question about the lack of research on its use for Androgenetic Alopecia (AGA).

The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.

User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

Oral minoxidil can cause multiple facial hairs to grow from one follicle, known as Pili Multigemini, leading to ingrown hairs and zits. Users report increased facial and body hair growth, with some experiencing fewer issues after switching to dutasteride.

The user is experiencing an itchy scalp after six months of using dutasteride and minoxidil, suspecting dutasteride as the cause. They are seeking advice on how to alleviate the itch without stopping the treatment.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Curcumin, found in turmeric, may reduce DHT levels and hair loss, similar to finasteride, but without its side effects. However, natural DHT blockers are generally considered too weak to make a significant difference in hair loss.

An experiment to determine the effectiveness of Pyrilutamide in reducing hair loss, using a regimen of Minoxidil and Finasteride, with promising results. The conversation also suggests comparing this to RU58841 as an alternative.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

Vitamin D and D3 are the same. Treatments discussed include Minoxidil, finasteride, and RU58841.

Hair loss discussion involves treatments like Minoxidil, Finasteride, and RU58841. Stemoxydine may be effective, but results may take at least 3 months due to hair cycle.

Users discuss using RU58841 with finasteride, dutasteride, and minoxidil for hair loss, noting reduced itching and effective results. Some users report no side effects, while others experience side effects with dutasteride.

The conversation discusses using dutasteride, both topical and oral, for hair loss in trans men, considering potential side effects like depression and libido issues. The user is exploring options including topical solutions with minoxidil, retinoic acid, and hydrocortisone, and plans to start microneedling.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.

User tried topical fin, dut, min, tret, hydrocortisone, microneedling, nizoral, collagen, propidren supplements, and laser helmet for hair loss with slow progress. They ask if topical spironolactone is a safer, effective alternative to RU for suppressing testosterone and treating hair loss in men.

Dutasteride and oral minoxidil improved the user's hair thickness, darkness, and curliness, making them look more attractive and younger. The user takes 0.5mg of dutasteride and 2.5mg of minoxidil daily.

A three-month progress report of using Dutasteride, oral Minoxidil, Ketoconazole shampoo, RU58841 and Dermarolling to combat hair loss. The results have been encouraging so far.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Combining Minoxidil with Finasteride or RU58841 may cause interference, irritation, or reduced absorption. It might be better to apply one topical at a time and wait an hour before applying another.